Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor targeting KIT mutations, including KIT D816V, for the treatment of Systemic Mastocytosis (SM) and gastrointestinal stromal tumors (GIST). The company has submitted New Drug Applications to the FDA for bezuclastinib in Non-Advanced SM, Advanced SM, and GIST, with commercial launch in the United States expected in 2026. The pipeline includes CGT4859, an FGFR2/3 inhibitor; CGT4255, a CNS-penetrant ErbB2 inhibitor; and CGT6297, a PI3Kα inhibitor, alongside preclinical programs targeting JAK2 and KRAS. Bezuclastinib was licensed from Plexxikon, a subsidiary of Daiichi Sankyo. The company maintains a discovery organization in Boulder, Colorado, and serves patients in the United States and select international markets.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage cogentbio.com
Sector Healthcare IR page investors.cogentbio.com
Tags
precision medicine, tyrosine kinase inhibitors, systemic mastocytosis, gastrointestinal stromal tumors, oncology, rare diseases, small molecule therapeutics, kinase inhibitors, Bezuclastinib, CGT9486, CGT4859, CGT4255, CGT6297, Plexxikon, Daiichi Sankyo
Press page —

Metrics

Valuation  
Market cap $ 5.571B
Market cap (USD) $ 5.571B
P/E -14.23
PEG —
P/BV 10.79
P/S 707.78
P/OCF -17.19
P/FCF -17.10
Dividend yield —
Turnover / mcap —
Returns  
ROE -73.7%
ROI -38.3%
ROIC -29.1%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 43.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 73
Quality score -86.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue — — — — — 7.871M 22.499M 9.734M 8.36M
Net profit -328.937M -255.859M -192.41M -140.241M -72.273M -74.808M -31.833M -34.532M -25.492M
Free cash flow -265.998M -208.364M -156.42M -125.501M -60.482M — -41.547M -33.038M -26.747M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 35.52 7.8 5.88 11.56 8.58 11.23 — — —
Price performance 12m 3.55 0.33 -0.49 0.35 -0.24 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 830,000 1.67M 2M — — — — — —
↳ YoY growth +101.0% +19.9%
Borrowings, non-current (USD) — — — — — — — — 0.00 —
Lease liabilities (USD) — — — 6.03M 5.21M 3.16M 19.6M 18.9M 17.5M 15.9M
Cash and deposits (USD) 42.6M 28.3M 55.7M 37.4M 242M 220M 140M 53.2M 98.2M 312M
Right-of-use assets (USD) — — — 5.29M 4.62M 2.77M 23.3M 22M 20.1M 18.1M
Net debt (borrowings + leases - cash) (USD) — — — — — — — — -80.7M —
Cash flow detail
Operating cash flow (USD) — -25.8M -32.5M -41.5M -35.9M -58.8M -119M -154M -208M -264M
Purchases of property, plant and equipment (USD) — -912,000 -549,000 -33,000 — -1.72M -6.86M -2.8M -573,000 -1.55M
Change in receivables (cash effect) (USD) — 98,000 -838,000 -332,000 2M — — — — —
Change in payables (cash effect) (USD) — -31,000 367,000 1.66M -2.45M 2.75M 2.36M 4.81M 1.36M -2.51M
Interest paid (cash effect) (USD) — — — — — — — 0.00 0.00 -2.02M
Income taxes paid (cash effect) (USD) — — — — — — — — — 0.00
Share-based compensation (USD) — 1.34M 3.09M 3.24M 6.02M 11.7M 18.4M 30.6M 39.7M 46.1M
Operating cash flow before change in receivables (USD) — -25.9M -31.7M -41.2M -37.9M — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) — -26.7M -33M -41.5M — -60.5M -126M -156M -208M -266M
Income detail
Research and development expense (USD) — 29.8M 38.3M 43.7M 25.7M 55.9M 122M 174M 233M 270M
↳ 5y CAGR +32.5% +35.3% +39.7% +60.0%
Total comprehensive income (USD) — -25.5M -34.5M -31.8M -74.8M -72.3M -140M -192M -256M -329M
Comprehensive income to owners (USD) — -25.5M -34.5M -31.8M -74.8M -72.3M -140M -192M -256M -329M
Reported May 14, 2018 Mar 28, 2019 Mar 28, 2019 Mar 26, 2020 Mar 16, 2021 Mar 14, 2023 Mar 14, 2023 Feb 17, 2026 Feb 17, 2026 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026

NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027

Cash balance of $791.1 million expected to fund operations into late 2028

WALTHAM, Mass. and BOULDER, Colo., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.

“With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “In parallel, our team is preparing for potential approvals in NonAdvanced and Advanced Systemic Mastocytosis and we expect to file INDs for our JAK2 and KRAS pipeline programs this quarter. Backed by a strong balance sheet and a world-class team, we are well positioned to continue our vision of creating best-in-class therapies for patients fighting rare, mutationally driven diseases.”

Business Highlights

  • Plan to present multiple posters featuring bezuclastinib at the 68th Annual Meeting of the American Society of Hematology (ASH) being held December 12-15, 2026, in New Orleans. Featured results will highlight more detailed analyses from the SUMMIT trial of bezuclastinib’s effects on skin and neurocognitive symptoms, longer term pathobiology follow-up and an MS2D2 symptomatic comparison of symptom burden in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients before and after bezuclastinib treatment with that of the general population. Included in these presentations will be the first look at clinical results from the SUMMIT sub-study, investigating the patient benefit of switching from avapritinib to bezuclastinib.

  • Announced the initiation of a single-arm, 40 patient extension cohort of the PEAK trial investigating the safety and efficacy of bezuclastinib in combination with sunitinib in first-line GIST patients. This cohort is designed to prospectively measure ORR and PFS in patients with either exon 9 or exon 11 primary mutations.

  • Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM).

Anticipated Upcoming Milestones

  • Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026

  • Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026

  • Potential FDA approval of bezuclastinib in AdvSM – PDUFA date of June 29, 2027

  • Investigational New Drug (IND) applications to be submitted for CGT1815, Cogent’s novel, selective pan-KRAS(ON) inhibitor, and CGT1145, Cogent’s novel, selective JAK2 V617F inhibitor in Q4 2026

  • Complete dose escalation for CGT4255, Cogent’s CNS-penetrant, selective mutant ErbB2 inhibitor

Upcoming Investor Conferences

  • Guggenheim Healthcare Innovation Conference on November 10 at 7:30 am ET

  • UBS Global Biopharma Conference on November 17 at 12:00 pm GMT (7:00 am ET)

  • Jefferies Global Healthcare Conference on November 17 at 5:00 pm GMT (12:00 pm ET)

  • Piper Sandler Healthcare Conference on December 1 at 11:00 am ET

The live webcasts can be accessed on the Investors & Media page of Cogent’s website at investors.cogentbio.com/events. A replay will be available approximately two hours after completion of each event and will be archived for up to 30 days.

Third Quarter 2026 Financial Results

**Cash Position:**As of September 30, 2026, cash, cash equivalents and marketable securities were $791.1 million, as compared to $792.3 million as of June 30, 2026. The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib.

R&D Expenses**:** Research and development expenses were $75.1 million for the third quarter of 2026 as compared to $69.0 million for the third quarter of 2025. The increase was primarily due to costs incurred to support our on-going SUMMIT, PEAK and APEX clinical trials and to the continued progression of our early stage, preclinical and discovery programs. R&D expenses include non-cash stock compensation expense of $7.5million for the third quarter of 2026 compared to $5.4 million for the third quarter of 2025.

**G&A Expenses:**General and administrative expenses were $42.1 million for the third quarter of 2026 as compared to $14.4 million for the third quarter of 2025. The increase was primarily due to continued investments in commercial readiness, including personnel and infrastructure to support the potential launch of bezuclastinib, as well as overall organizational growth. G&A expenses include non-cash stock compensation expense of $9.4 million for the third quarter of 2026 compared to $5.2 million for the third quarter of 2025.

**Net Loss:**Net loss was $111.4 million for the third quarter of 2026 as compared to a net loss of $80.9 million for the same period of 2025.

About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced Gastrointestinal Stromal Tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: potential FDA approval and commercial launch of bezuclastinib in GIST; potential FDA approval of bezuclastinib in both NonAdvSM and AdvSM; cash runway expected to fund operations into late 2028 and well past all three pending PDUFA action dates for bezuclastinib; plans to submit INDs for the company’s JAK2 and KRAS pipeline programs and to move into clinical development soon; plans to complete dose escalation for CGT4255; and plans to present multiple poster presentations featuring bezuclastinib at ASH 2026 and the contents of those presentations. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Quarterly Report on Form 10-Q filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

| COGENT BIOSCIENCES, INC. |

| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |

| (in thousands) |

| (unaudited) |

| |

| | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Operating expenses: | | | | | | | | | | | |

| Research and development | $ | 75,099 | | | $ | 68,989 | | | $ | 221,275 | | | $ | 194,221 | |

| General and administrative | | 42,085 | | | | 14,366 | | | | 102,154 | | | | 39,649 | |

| Total operating expenses | | 117,184 | | | | 83,355 | | | | 323,429 | | | | 233,870 | |

| Loss from operations | | (117,184 | ) | | | (83,355 | ) | | | (323,429 | ) | | | (233,870 | ) |

| Other income: | | | | | | | | | | | |

| Interest income | | 7,052 | | | | 3,887 | | | | 22,121 | | | | 9,212 | |

| Interest expense | | (1,243 | ) | | | (1,459 | ) | | | (3,673 | ) | | | (1,773 | ) |

| Other expense, net | | (51 | ) | | | (3 | ) | | | (202 | ) | | | (14 | ) |

| Total other income, net | | 5,758 | | | | 2,425 | | | | 18,246 | | | | 7,425 | |

| Net loss | $ | (111,426 | ) | | $ | (80,930 | ) | | $ | (305,183 | ) | | $ | (226,445 | ) |

| COGENT BIOSCIENCES, INC. |

| SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA |

| (in thousands) |

| (unaudited) |

| |

| | | September 30, | | | December 31, | |

| | | 2026 | | | 2025 | |

| Cash, cash equivalents and marketable securities | | $ | 791,134 | | | $ | 900,765 | |

| Working capital | | $ | 730,466 | | | $ | 846,402 | |

| Total assets | | $ | 832,142 | | | $ | 937,607 | |

| Total liabilities | | $ | 315,884 | | | $ | 301,236 | |

| Total stockholders’ equity | | $ | 516,258 | | | $ | 636,371 | |

October 27, 2026

PDF Version

WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Tuesday, November 10, 2026 at 7:30 a.m. ET.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cogent also announced today that on October 26, 2026, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to six new employees under the company’s 2020 Inducement Plan with grant dates of October 26, 2026. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, (i) nonqualified options to purchase 22,000 shares of Cogent common stock and (ii) 16,500 restricted stock units (RSUs). Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. The RSUs vest annually in equal installments over 4 years from the grant date, provided such employee remains employed through each such vesting date.

About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced Gastrointestinal Stromal Tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

September 15, 2026

PDF Version

NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM

PDUFA target action date set for June 29, 2027

WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2027. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues.

“With the FDA’s acceptance of our NDA in Advanced Systemic Mastocytosis, we have reached another important regulatory milestone for bezuclastinib and are one step closer to potentially bringing this therapy to patients with AdvSM,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “Together with the NDAs currently under review for NonAdvSM and GIST patients, this milestone further reinforces the potential of bezuclastinib across multiple patient populations with KIT-driven diseases. With an excellent commercial and medical team in place, we are excited and ready for the potential launches later this year.”

The NDA acceptance is supported by data from the APEX pivotal trial, which was most recently presented at the 2026 European Hematology Association (EHA) Congress, in which bezuclastinib demonstrated clinically meaningful responses and durable clinical activity in patients with AdvSM. As of the March 31, 2026 data cutoff, the primary endpoint of response per mIWG-MRT-ECNM criteria demonstrated a 65% overall response rate, including 57% of patients achieving CR, CRh or PR as best response. Response by pure pathological response (PPR) criteria was 81%. Bezuclastinib also demonstrated durable clinical activity, with a 12-month progression-free survival rate of 79% and 12-month overall survival rate of 87%, with median PFS and OS not yet mature.

Cogent continues to advance bezuclastinib toward potential approvals and commercialization across its three indications. The Company’s NDA for NonAdvanced Systemic Mastocytosis is under FDA review, with a PDUFA target action date of December 30, 2026, and the NDA for GIST is also under FDA review, with a PDUFA target action date of November 30, 2026. Together, these regulatory milestones represent significant progress toward bringing bezuclastinib to patients across a broad spectrum of KIT-driven diseases.

Bezuclastinib - Expanded Access Program Working with the FDA, Cogent has established active Expanded Access Programs (EAPs) for U.S. patients with SM or GIST who meet disease-specific criteria and could benefit from treatment with bezuclastinib or the combination of bezuclastinib and sunitinib. For more information please visit: https://www.cogentbio.com/bezuclastinib-program-development/#our-expanded-access-policy.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cogent also announced today that, on September 10, 2026, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to nine new employees under the company’s 2020 Inducement Plan with grant dates of September 10, 2026 and September 14, 2026. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, (i) nonqualified options to purchase 39,300 shares of Cogent common stock and (ii) 33,600 restricted stock units (RSUs). Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. The RSUs vest annually in equal installments over 4 years from the grant date, provided such employee remains employed through each such vesting date.

About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the potential for regulatory approval and commercialization of bezuclastinib across three indications: patients with GIST, NonAdvSM and AdvSM; bezuclastinib’s potential across multiple KIT-driven diseases and the potential commercial launches of bezuclastinib later this year. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Quarterly Report on Form 10-Q filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Prompts

Cogent Biosciences, Inc. (ticker COGT), listed in United States.

Company History

Date Change Detail
Aug 12, 2020 Renamed UNUM THERAPEUTICS INC. → COGENT BIOSCIENCES, INC.

ETFs Holding Cogent Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 6.48% 233,781 $ 8.182M Aug 31, 2026
CANC 4.70% 283,440 $ 9.92M Aug 31, 2026
FMED 2.31% 34,000 $ 1.19M Aug 31, 2026
JSML 0.62% 57,786 $ 2.25M Jul 31, 2026
ESSC 0.44% 4,046 $ 157.511K Jul 31, 2026
FSEG 0.40% 590 $ 22.833K Jun 30, 2026
BMED 0.35% 1,813 $ 49.749K Nov 16, 2026
RUSC 0.31% 6,363 $ 246.248K Jun 30, 2026
MMSC 0.25% 4,471 $ 122.684K Nov 16, 2026
FFSM 0.25% 95,539 $ 3.719M Jul 31, 2026
FESM 0.20% 291,782 $ 11.292M Jun 30, 2026
RESM 0.18% 173 $ 6,695.10 Jun 30, 2026
FTKI 0.18% 1,697 $ 46.566K Nov 16, 2026
VFMV 0.18% 23,110 $ 808.85K Aug 31, 2026
TMSL 0.12% 83,026 $ 3.213M Jun 30, 2026
VFMO 0.11% 57,790 $ 2.023M Aug 31, 2026
WSGE 0.06% 1,325 $ 36.901K Nov 18, 2026
FSEV 0.06% 96 $ 3,715.20 Jun 30, 2026
FTLS short -0.04% -40,245 $ 0.00 Nov 16, 2026
MSSM 0.03% 6,535 $ 228.725K Aug 31, 2026
AVIE 0.03% 210 $ 5,762.40 Nov 16, 2026
IALT short 0.00% -9,021 $ -247.536K Nov 16, 2026
NTRL short 0.00% -1,413 $ 0.00 Nov 16, 2026